Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant nituzumab + ipilimumab for resectable head and neck squamous cell carcinoma
ChiCTR2200063496Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nimotuzumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: pathological complete response, major pathological response and 2 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
nimotuzumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200063496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063496.